Himalaya Early Access Program

Part of paid clinical trials in Newark, Delaware.

Sponsor
AstraZeneca
Study ID
NCT05345678
Status
Approved For Marketing

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To provide early access (i.e., before marketing authorisation) to tremelimumab 300 mg IV administered once on Day 1 of Cycle 1 plus durvalumab 1500 mg IV followed by durvalumab 1500 mg IV Q4W monotherapy in patients with unresectable HCC.

Key Dates

First listed
Apr 26, 2022
Status verified
Dec 2022

Locations (4)

FacilityCityStateZIPSite coordinators
Research SiteNewarkDelaware19718-
Research SiteMinneapolisMinnesota55404-
Research SiteRenoNevada89502-
Research SiteMorgantownWest Virginia26506-

Find similar trials in Newark, DE

Nationwide
Liver cancer trialsOncology trialsGI oncology trialsHepatology trials
By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology

Related Studies